Yellow Jersey Therapeutics Ag

This was an early-stage study to check the basic safety of a new injectable drug called NM26-2198 for people with moderate-to-severe eczema (atopic dermatitis). It involved 126 healthy volunteers and eczema patients to see how their bodies handled single and multiple doses. The m…